GZYK(SZ:002524)2022-11-09 16:00Financial Performance - The company's operating revenue for Q3 2022 was CNY 230.93 million, a decrease of 7.82% compared to CNY 250.53 million in the same period last year[5] - Net profit attributable to shareholders for Q3 2022 reached CNY 195.90 million, an increase of 1,381.39% from CNY 15.29 million year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.38, a substantial increase of 1,366.67% from a loss of CNY 0.03 in the same period last year[5] - Total operating revenue for the third quarter was ¥572,261,800.05, a decrease of 26.5% compared to ¥778,715,206.97 in the same period last year[20] - The net profit for Q3 2022 reached ¥133 million, representing a significant increase of 192% from ¥45.5 million in Q3 2021[21] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was CNY 96.15 million, a significant increase of 219.46% compared to CNY 30.10 million in the previous year[5] - Operating cash flow increased by 219.46% to CNY 96,148,574.83, driven by reduced cash payments for goods and services[11] - Cash and cash equivalents increased by 100.76% to CNY 117.09 million, primarily due to the redemption of financial products and receipt of financing lease payments[10] - The company reported a net cash increase of ¥63.8 million for the quarter, contrasting with a net decrease of ¥33.6 million in the same quarter last year[23] - Financing activities generated a net cash inflow of ¥10.5 million, a recovery from a net outflow of ¥105 million in Q3 2021[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.80 billion, reflecting a decrease of 1.51% from CNY 1.83 billion at the end of the previous year[5] - Total current assets rose to ¥354,333,044.67, up 4.6% from ¥340,544,140.75[18] - Total liabilities decreased to ¥1,315,616,375.16, down 11.6% from ¥1,487,473,228.26[18] - The company’s total assets decreased to ¥1,801,239,243.01 from ¥1,828,855,610.04, a decline of 1.5%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,905[13] - The largest shareholder, Guangzheng Investment Co., Ltd., holds 25.06% of shares, amounting to 129,168,708 shares, with 80,045,000 shares pledged[13] Expenses and Investments - Sales expenses decreased by 32.87% to CNY 103,121,314.94, primarily due to reduced personnel and marketing investments impacted by the pandemic[11] - R&D expenses decreased by 71.88% to CNY 543,215.59, indicating a reduction in research and development activities[11] - Investment income decreased by 103.42% to a loss of CNY 2,454,145.01, primarily due to the previous year's gain from the disposal of subsidiary equity[11] - Long-term equity investments increased to ¥34,985,532.29 from ¥28,191,302.26, reflecting a growth of 24.0%[18] Market Strategy - The company plans to continue expanding its market presence and developing new technologies in the ophthalmology sector[5] - The company did not report any significant new product launches or technological advancements during this quarter[24] Other Financial Metrics - The company reported a significant decrease in non-operating income, with a total of CNY 212.38 million for the current period, down from CNY 213.67 million[7] - Prepayments decreased by 75.73% to CNY 679,128.17 due to reduced real estate leasing prepayments[11] - Contract liabilities increased by 635.40% to CNY 79,006,073.42 due to an increase in contract prepayments[11] - The company experienced a decrease in cash inflow from operating activities, totaling ¥691 million, down from ¥817 million year-over-year[22] - The operating cash flow for the period was ¥96.1 million, up from ¥30.1 million in the previous year, indicating improved cash generation capabilities[22]